22nd Century Group logo
XXII22nd Century Group
Trade XXII now
22nd Century Group primary media

About 22nd Century Group

22nd Century Group (NASDAQ:XXII) focuses on biotechnology, striving to decrease the harm caused by smoking through its proprietary tobacco products that have reduced nicotine content. Additionally, the company works on hemp/cannabis research to develop new plant varieties with specific cannabinoid profiles. With a mission geared towards improving health and reducing the impacts of smoking, 22nd Century Group is dedicated to advancing agricultural biotechnology projects and bringing to market tobacco with potentially less addictive properties, alongside exploring the growing potentials of cannabis for various uses. This combination of objectives underscores their commitment to public health and innovation in plant science.

What is XXII known for?

Snapshot

Public US
Ownership
1998
Year founded
198
Employees
Williamsville, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Produtos e/ou serviços de 22nd Century Group

  • VLN cigarettes, designed to contain 95% less nicotine compared to traditional cigarettes, aiming to help smokers reduce their nicotine consumption.
  • Development of proprietary tobacco plants with non-addictive levels of nicotine, to support the creation of reduced-risk tobacco products.
  • Research and production of hemp/cannabis plants with specific cannabinoid profiles for medical, wellness, and pharmaceutical applications.
  • Genetically engineered tobacco and hemp plants for improved crop yields and resistance to diseases and pests, enhancing agricultural efficiency.
  • Sublicensing of their technology and plant varieties to other companies in the tobacco and hemp industries, diversifying their revenue streams.
  • Consultancy services for biotechnology and agricultural firms, leveraging their expertise in plant biotechnology and genetics.

equipe executiva do 22nd Century Group

  • Mr. Lawrence D. FirestonePresident, CEO & Director
  • Mr. Daniel A. OttoCFO & Principal Accounting Officer
  • Mr. Scott MarionVice President of Operations
  • Mr. Jonathan StaffeldtGeneral Counsel & Secretary
  • Mr. Robert P. ManfredoniaExecutive Vice President of Sales
  • Dr. Kimberly Farr Ph.D.Director of Science & Technology
  • Matthew KrepsInvestor Relations
  • Mr. James C. MorrisonTechnical Advisor & Regulatory Affairs Consultant

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.